LSTA

Lisata Therapeutics, Inc. (LSTA) - Q1 2026 10-Q Summary

Business Context and Reporting Period

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company developing certepetide, a tumor-penetrating peptide designed to enhance the delivery of anti-cancer therapies to solid tumors. This report covers the quarterly period ended March 31, 2026. The Company is currently a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $0.9 million (15.5%) to $4.9 million.
  • Research & Development (R&D): Decreased by $1.4 million (53.7%) to $1.2 million, primarily due to the completion of the Phase 2a BOLSTER trial and reduced clinical department staffing.
  • General & Administrative (G&A): Increased by $0.5 million (15.2%) to $3.7 million, driven by higher legal and consulting fees related to the proposed acquisition by Kuva Labs, Inc.
• Liquidity: Cash and cash equivalents decreased by $2.9 million from the beginning of the period, reflecting net operating cash outflows of $3.1 million.
• Income Tax Benefit: Recognized a $0.4 million benefit from the sale of New Jersey net operating losses (NOLs) in February 2026.

Outlook, Risks, and Material Events

• Proposed Acquisition by Kuva Labs, Inc.: On March 6, 2026, Lisata entered into a Merger Agreement to be acquired by Kuva Labs. The offer price is $5.00 per share in cash plus one Contingent Value Right (CVR) worth up to $1.00 if a New Drug Application is filed for certepetide within seven years.
  • The tender offer commencement date was extended to May 29, 2026.
  • Kuva has agreed to pay up to $1.1 million of Lisata's expenses until the offer commences.
  • Completion is not guaranteed; failure to close could result in a $2.0 million termination fee payable to Lisata under certain circumstances.
• Going Concern: Management has concluded there is substantial doubt regarding the Company's ability to continue as a going concern for twelve months following the report date due to a history of losses and the need for additional funding. The financial statements do not include adjustments that might be necessary if the Company cannot continue.
• License Terminations:
  • Qilu Pharmaceutical: The exclusive license for certepetide in Greater China was mutually terminated on January 23, 2026. Rights reverted to Lisata.
  • Kuva Labs License: A separate exclusive license agreement with Kuva regarding NanoMark imaging technology was terminated in December 2025 due to Kuva's default on payment obligations.
• Clinical Progress: Preliminary data from the ASCEND trial (Cohort B) showed improved progression-free survival and objective response rates for certepetide combined with chemotherapy in pancreatic cancer. The BOLSTER trial in cholangiocarcinoma showed no evidence of benefit.

Investor Verification Checklist

• Acquisition Timeline: Verify if Kuva Labs commences the tender offer by the May 29, 2026 deadline and whether the $1.1 million expense reimbursement is received.
• Cash Runway: Assess the sufficiency of the $13.1 million cash balance to fund operations if the acquisition fails to close and additional capital cannot be raised.
• Going Concern Status: Review management's specific plans to alleviate liquidity risks, including potential equity issuances or asset sales.
• ASCEND Trial Data: Monitor the release of the final study report for the ASCEND trial to confirm the clinical efficacy trends observed in preliminary data.
• Qilu Termination Impact: Confirm the status of the Phase 2 CEND1-202 trial data in China, as Lisata does not own the rights to this data following the termination.